Business
Notice of AGM
Notice of AGM.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 3900W Hemogenyx Pharmaceuticals PLC 14 November 2017 \n\nHemogenyx Pharmaceuticals Plc\n(\"Hemogenyx\" or the \"Company\")\n \nNotice of AGM\n \nHemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Notice of the Annual General Meeting (\"AGM\") was sent to shareholders yesterday. \n \nThis document is available to view on the company website: www.hemogenyx.com \n \nThe AGM is to be held at 10:00am on Thursday 7 December 2017 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD. \n \n \nEnquiries:\n \n\n\n\n\nHemogenyx Pharmaceuticals Limited\n\n\nwww.hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\nVia Walbrook PR\n\n\n\n\nDr Robin Campbell, Chairman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOptiva Securities Ltd\n\n\nTel: +44 (0)20 3137 1902\n\n\n\n\nChristian Dennis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\nTel: +44 (0)20 7186 9950\n\n\n\n\nDamon Heath, Erik Woolgar\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeterhouse Corporate Finance Limited\n\n\nTel: +44 (0)20 7469 0930\n\n\n\n\nLucy Williams/Duncan Vasey\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout Hemogenyx Pharmaceuticals Plc\nHemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantati...